
Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 713-794-4999
Dr. Puduvalli is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Clinical Expertise
- Neuro-oncology, Glioblastoma, Astrocytoma, Oligodendroglioma, Gliomas, Primary brain tumors, Metastatic brain tumors, Cancer Neurology
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 1996 - 1998
University of Texas Health Science Center at HoustonResidency, Neurology, 1993 - 1996
Texas Tech University (Amarillo)Internship, Internal Medicine, 1992 - 1993
Bangalore Medical CollegeClass of 1983
Certifications & Licensure
AZ State Medical License 2023 - 2026
GA State Medical License 2023 - 2026
MS State Medical License 2023 - 2026
OK State Medical License 2023 - 2026
TX State Medical License 1997 - 2026
AL State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
American Board of Psychiatry and Neurology Neurology- Join now to see all
Awards, Honors, & Recognition
- Beau Biden Endowed Chair in Brain Cancer Research UT MD Anderson Cancer Center, 2021
- Top Doctors in Columbus Columbus Monthly
- America's Top Doctors Castle Connolly
Clinical Trials
- Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) Start of enrollment: 2007 Nov 28
- Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I Start of enrollment: 2008 Apr 29
- Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) Start of enrollment: 2011 Jun 01
Publications & Presentations
PubMed
- F-FDG PET Reveals Voxel-Based Decreases in Brain Glucose Uptake After Chemotherapy in Leukemia Patients: A Retrospective Matched-Control Study.Ahmed Msherghi, Franklin Wong, Guofan Xu, Osama Mawlawi, Muhammed Elhadi
Journal of Nuclear Medicine. 2025-12-03 - Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses : Treatment intens...Debra Nana Yeboa, Benjamin T Whitfield, Ruitao Lin, Chinenye Lynette Ejezie, Todd A Swanson
Journal of Neuro-Oncology. 2025-11-05 - Single center experience of IDH inhibitors in recurrent high-grade gliomas.Catherine R Garcia, Kaitlin Highsmith, Stephanie Knight, Ivan Pradilla Andrade, Cheuk Hong Leung
Journal of Neuro-Oncology. 2025-11-01
Grant Support
- Characterization of Onalespib, A novel long acting Hsp90 inhibitor, as a chemo and radiosensitizer in Adults with Newly Diagnosed GlioblastomaNational Cancer institute2019–2025
- Patient Oriented Research Program In Neuro-OncologyNational Cancer Institute2012
- Efficacy And Toxicity Of Trail Against GliomasNational Cancer Institute2006–2010
- Correlative Trial Of Fenretinide Against GlioblastomasNational Cancer Institute2002–2003
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:













